CYCCP Fundamental Analysis - CYCLACEL PHARMACEUTICALS - CYCC 6 PERP

Fundamental Rating

Taking everything into account, CYCCP scores 3 out of 10 in our fundamental rating. CYCCP was compared to 560 industry peers in the Biotechnology industry. CYCCP has a great financial health rating, but its profitability evaluates not so good. CYCCP is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

CYCCP had negative earnings in the past year.

In the past year CYCCP has reported a negative cash flow from operations.

CYCCP had negative earnings in each of the past 5 years.

In the past 5 years CYCCP always reported negative operating cash flow.

1.2 Ratios

CYCCP's Return On Assets of -223.54% is on the low side compared to the rest of the industry. CYCCP is outperformed by 90.89% of its industry peers.

With a Return On Equity value of -272.60%, CYCCP is not doing good in the industry: 71.61% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-223.54%
ROE	-272.6%
ROIC	N/A

ROA(3y)-203.37%

ROA(5y)-137.74%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYCCP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CYCCP does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CYCCP has been increased compared to 1 year ago.

The number of shares outstanding for CYCCP has been reduced compared to 5 years ago.

There is no outstanding debt for CYCCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -103.79, we must say that CYCCP is in the distress zone and has some risk of bankruptcy.

CYCCP's Altman-Z score of -103.79 is on the low side compared to the rest of the industry. CYCCP is outperformed by 97.32% of its industry peers.

CYCCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-103.79

ROIC/WACCN/A

WACC9.47%

2.3 Liquidity

CYCCP has a Current Ratio of 5.60. This indicates that CYCCP is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 5.60, CYCCP is in line with its industry, outperforming 59.46% of the companies in the same industry.

CYCCP has a Quick Ratio of 5.60. This indicates that CYCCP is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CYCCP (5.60) is better than 60.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.6
Quick Ratio	5.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CYCCP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.57%, which is quite impressive.

CYCCP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.86%.

EPS 1Y (TTM)44.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.72%

Revenue 1Y (TTM)-96.86%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

CYCCP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.35% yearly.

Based on estimates for the next years, CYCCP will show a very strong growth in Revenue. The Revenue will grow by 385.15% on average per year.

EPS Next Y39.49%

EPS Next 2Y19.4%

EPS Next 3Y57.16%

EPS Next 5Y36.35%

Revenue Next Year88.68%

Revenue Next 2Y37.36%

Revenue Next 3Y1049.89%

Revenue Next 5Y385.15%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYCCP. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCCP. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CYCCP's earnings are expected to grow with 57.16% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.4%

EPS Next 3Y57.16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CYCCP has a Yearly Dividend Yield of 4.00%. Purely for dividend investing, there may be better candidates out there.

The stock price of CYCCP dropped by -43.34% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.

CYCCP's Dividend Yield is rather good when compared to the industry average which is at 113.28. CYCCP pays more dividend than 99.29% of the companies in the same industry.

CYCCP's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.

		Industry Rank	Sector Rank
Dividend Yield	4%

5.2 History

The dividend of CYCCP decreases each year by -37.25%.

CYCCP has been paying a dividend for over 5 years, so it has already some track record.

The dividend of CYCCP decreased in the last 3 years.

Dividend Growth(5Y)-37.25%

Div Incr Years0

Div Non Decr Years2

5.3 Sustainability

DP0%

EPS Next 2Y19.4%

EPS Next 3Y57.16%

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP

NASDAQ:CYCCP (5/30/2025, 8:00:00 PM)

+0.4 (+11.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-12 2025-05-12

Earnings (Next)08-12 2025-08-12

Inst Owners6.51%

Inst Owner Change11371.9%

Ins Owners0.91%

Ins Owner ChangeN/A

Market Cap89.08M

Analysts43.33

Price Target18.95 (373.75%)

Short Float %0%

Short Ratio0

Dividend

		Industry Rank	Sector Rank
Dividend Yield	4%

Yearly Dividend0.03

Dividend Growth(5Y)-37.25%

DP0%

Div Incr Years0

Div Non Decr Years2

Ex-Date04-29 2025-04-29 (0.15)

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-100%

Min Revenue beat(2)-100%

Max Revenue beat(2)-100%

Revenue beat(4)1

Avg Revenue beat(4)-47.71%

Min Revenue beat(4)-100%

Max Revenue beat(4)96.08%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6362.86
P/FCF	N/A
P/OCF	N/A
P/B	29.09
P/tB	29.09
EV/EBITDA	N/A

EPS(TTM)-8.79

EYN/A

EPS(NY)-1.14

Fwd EYN/A

FCF(TTM)-0.48

FCFYN/A

OCF(TTM)-0.48

OCFYN/A

SpS0

BVpS0.14

TBVpS0.14

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-223.54%
ROE	-272.6%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-203.37%

ROA(5y)-137.74%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.6
Quick Ratio	5.6
Altman-Z	-103.79

F-Score3

WACC9.47%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)44.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.72%

EPS Next Y39.49%

EPS Next 2Y19.4%

EPS Next 3Y57.16%

EPS Next 5Y36.35%

Revenue 1Y (TTM)-96.86%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year88.68%

Revenue Next 2Y37.36%

Revenue Next 3Y1049.89%

Revenue Next 5Y385.15%

EBIT growth 1Y43.6%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y48.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y48.57%

OCF growth 3YN/A

OCF growth 5YN/A

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens